This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Start Date-

Sponsor / Collaborator

Calico LLC

NCT04777994 / RecruitingPhase 1

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).
The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy).
Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors.
Part 2, ABBV-CLS-484 will be administered at escalating dose levels in combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors.
Part 3, ABBV-CLS-484 will be administered alone as a monotherapy at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1 targeting or with a VEGFR TKI agent in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.

Start Date09 Mar 2021

Sponsor / Collaborator

AbbVie, Inc.

[+1]

100 Clinical Results associated with Osunprotafib

100 Translational Medicine associated with Osunprotafib

100 Patents (Medical) associated with Osunprotafib

Literatures (Medical) associated with Osunprotafib

01 Jun 2024·MedComm

Little ones can do big things: Small molecule inhibitors target PTPN2/PTPN1 for tumor immunotherapy

Article

Author: Zhang, Anren ; Qin, Shugang ; Wang, Junyu

AC484 was developed by designing compounds based on the PTPN2 protein structure. AC484 enhances antitumor immunity through multiple mechanisms: increasing tumor sensitivity to IFN-γ, improving T-cell functions, stimulating tumor microenvironment inflammation, expanding TCR diversity, and preventing T-cell exhaustion. Interestingly, the efficacy of AC484 was also mediated by CD8+ and NK cells.

12 Dec 2023·Cancer Discovery

A Dual PTPN2/PTPN1 Active-Site Inhibitor Promotes Antitumor Immunity

AbstractABBV-CLS-484, an active-site inhibitor of PTPN2/PTPN1, elicits immune-dependent antitumor efficacy.

26 Oct 2023·NatureQ1 · CROSS-FIELD

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Q1 · CROSS-FIELD

Article

Author: Longenecker, Kenton ; Trusk, Patricia ; Halliwill, Kyle ; Yates, Kathleen B ; Fossey, Stacey ; Cheruiyot, Collins K ; Xiong, Zhaoming ; Klinge, Kelly L ; Qiu, Wei ; Baumgartner, Christina K ; Iracheta-Vellve, Arvin ; Avila, Omar I ; Rees, Matthew G ; Bulic, Marinka ; Farney, Elliot P ; Kohnle, Ian C ; El-Bardeesy, Nabeel ; Wu, Meng-Ju ; Guffroy, Magali ; Patel, Chirag H ; Chen, Angeline ; Manguso, Robert T ; Backus, Carey ; Kennedy, Domenick E ; Mathew, Rebecca ; Kym, Philip R ; Knudsen, Nelson H ; Balon, Tyler M ; Frost, Jennifer M ; Decker, Joshua H ; Tiwari, Payal ; McGuire, Kathleen A ; Liu, Yue ; Krishnan, Navasona ; Sun, Im-Meng ; Ebrahimi-Nik, Hakimeh ; Colvin, Kayla J ; Paddock, Marcia N ; Geda, Prasanthi ; Hutchins, Charles W ; Mu, Liang ; Dunning, Jax P ; Yeary, Mitchell D ; Suermondt, Juliette S M T ; Kammula, Ashwin V ; Golub, Todd R ; Davis, Thomas G R ; Yang, Yi ; Muscato, Audrey J ; Matulenko, Mark A ; Hrusch, Cara L ; Kim, Sarah Y ; Klahn, Joseph T ; Beauregard, Clay ; Halvorsen, Geoff T ; Sen, Debattama R ; Olander, Kira E ; Boghossian, Andrew ; Chuong, Cun Lan ; Patti, James C ; Duggan, Ryan ; Hamel, Keith M ; Sun, Qi ; Roth, Jennifer A ; Ronan, Melissa ; Griffin, Gabriel K

AbstractImmune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity3–6. However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable. Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor. AC484 treatment in vitro amplifies the response to interferon and promotes the activation and function of several immune cell subsets. In mouse models of cancer resistant to PD-1 blockade, AC484 monotherapy generates potent anti-tumour immunity. We show that AC484 inflames the tumour microenvironment and promotes natural killer cell and CD8+ T cell function by enhancing JAK–STAT signalling and reducing T cell dysfunction. Inhibitors of PTPN2 and PTPN1 offer a promising new strategy for cancer immunotherapy and are currently being evaluated in patients with advanced solid tumours (ClinicalTrials.gov identifier NCT04777994). More broadly, our study shows that small-molecule inhibitors of key intracellular immune regulators can achieve efficacy comparable to or exceeding that of antibody-based immune checkpoint blockade in preclinical models. Finally, to our knowledge, AC484 represents the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy and may pave the way for additional therapeutics that target this important class of enzymes.

News (Medical) associated with Osunprotafib

07 Aug 2024

·www.echemi.com

Boehringer Ingelheim's Path to Cancer Research and development: From Acquisitions to the Rise of Innovative Drugs

On July 29, Boehringer Ingelheim announced a major acquisition, with plans to buy Nerio Therapeutics for $1.3 billion. Nerio Therapeutics, a pharmaceutical company focused on phosphatase research, has successfully developed highly selective phosphatase PTPN2/N1 inhibitors for an innovative regimen of tumor immunotherapy. With a leading position in the global oncology market, Boehringer Ingelheim has continuously strengthened its strategic presence in oncology in recent years. According to preliminary statistics, the company has established cooperative relationships with a number of well-known pharmaceutical companies in recent years to accelerate the construction of tumor research and development pipelines: In December 2020, Boehringer Ingelheim acquired NBE Therapeutics for 1.18 billion euros to acquire novel antibody-coupled drugs to address the challenge of refractory solid tumors. In the same month, Boehringer Ingelheim acquired Labor Dr. Merk & Kollegen to increase its research and development and clinical manufacturing capabilities to support its next generation cancer immune drug development program. In January 2021, the company entered into a strategic partnership with Enara Bio to develop innovative cancer immunotherapies using its Dark Antigen™ platform. In September 2021, Boehringer Ingelheim acquired Abexxa Biologics to gain expertise in targeting cancer-specific proteins within cells, expanding the range of potential cancer antigen targets. In June 2022, the company entered into A global licensing agreement with the Agency for Science, Technology and Research of Singapore (A*STAR) to acquire the development and commercialization rights for A*STAR's series of innovative tumor-specific antibodies. In January 2023, Boehringer Ingelheim and 3T Biosciences entered into a strategic collaboration and licensing agreement to jointly explore and develop the next generation of cancer therapies. In March 2023, the company partnered with Covant Therapeutics to develop a covalent drug candidate for the ADAR1 cancer target. In November 2023, Boehringer Ingelheim acquired T3 Pharmaceuticals for CHF 450 million (approximately $508 million), which specializes in innovative therapeutic platforms that enhance immunotherapy with live bacteria. In the same month, Boehringer Ingelheim established a strategic collaboration and licensing agreement with Phenomic AI to jointly discover key targets in rich stromal cancers. In February 2024, Boehringer Ingelheim and CBmed entered into a long-term strategic partnership to accelerate the development of first-of-its-kind oncology drugs using translational medicine to improve the lives of patients. In May 2024, Boehringer Ingelheim and OSE expanded their collaboration to jointly develop first-of-its-kind therapies for tumor and cardio-renal metabolic diseases, including the anti-SIRRP α tumor Immunity program and the cis targeted anti-PD1 / cytokine platform. While Boehringer Ingelheim does not yet have a significant oncology product in the market, its oncology pipeline includes several promising candidates, such as Zongertinib(Phase 1), Brigimadlin (Phase two-thirds) and BI-764532 (Phase 2). Zongertinib is an innovative covalently bound, orally effective and selective HER2 small molecule inhibitor. It covalently binds to the tyrosine kinase domain (TKD) of both wild-type and mutant HER2 receptors, including exon 20 mutations, while preserving the wild-type signal of EGFR, thereby demonstrating good tolerability and safety while ensuring efficacy. Data from the Phase 1a/1b clinical study of Zongertinib monotherapy for HER2-variant advanced solid tumors (NCT04886804), presented at the ASCO meeting in 2024, showed that Zongertinib demonstrated superior efficacy and was well tolerated in patients with HER2-mutation-positive advanced NSCLC. Brigimadlin is a mouse dual microhomologous gene 2 (MDM2) -p53 antagonist targeting MDM2-amplified tumors such as biliary adenocarcinoma, non-small cell lung cancer, and pancreatic cancer. Currently, Brigimadlin's first-line treatment of dedifferentiated liposarcoma (DDLPS) has entered phase 2/3 of clinical trials. New results from the Phase 1a/1b study (NCT03449381) presented at the ASCO Meeting in 2024 show that Brigimadlin induces proteomic changes in DDLPS that may serve as potential biomarkers for predicting treatment response and adverse events. BI 764532 is a first-in-class T cell-mediated bisspecific antibody developed at Boehringer Ingelheim that induces a patient's own T cells to attack cancer cells expressing DLL3. BI 764532 has received fast track approval from the FDA for the treatment of advanced SCLC and advanced or metastatic extrapulmonary neuroendocrine carcinoma. In both DLL3-positive cell and xenograft models, BI 764532 showed potential preclinical antitumor activity. PTPN2 and PTPN1 (also known as PTP-1B) are phosphatases that negatively regulate multiple cytokine signaling pathways and T cell receptor (TCR) signaling pathways. They inhibit inflammation by dephosphorylation of JAK and STAT family members, and reduce T-cell sensitivity to antigens by phosphorylation of LCK and FYN. PTPN2 deletion was found to increase the number of activated cytotoxic CD8+T cells in the tumor, improve antigen presentation and sensitivity to IFNγ, and thus enhance tumor sensitivity to CD8+T cells. Given the critical role of PTPN2/N1 in tumor and immune cells and its highly conserved active sites, researchers are developing PTPN2/N1 inhibitors. Currently, there are several PTPN2/N1 inhibitors, such as ABBV-CLS-579 and ABBV-CLS-484 (AC484). AC484 is an oral PTPN2/N1 active site inhibitor that enhances the response to interferon and promotes the activation and function of immune cell subsets. In a PD-1-resistant mouse model, AC484 monotherapy showed significant antitumor effects. Currently, a Phase 1 clinical trial of AC484 is underway to evaluate its efficacy alone or in combination with PD-1 inhibitors or VEGFR tyrosine kinase inhibitors (TKI) in the treatment of advanced or metastatic solid tumors. In addition, using Chemistry42, its generating-AI platform, Insili has also developed a novel PTPN2/N1 inhibitor that has drug-like properties, good oral bioavailability in vivo, and strong in vivo anti-tumor activity, demonstrating nanoscale inhibitory efficacy.

Phase 1ImmunotherapyLicense out/in

05 Oct 2023

·www.fiercebiotech.com

AbbVie and Calico immunotherapy boosts PD-1 response and tackles T cell exhaustion in mice

Besides demonstrating that it’s possible to target a phosphatase, the drug may also provoke the pharmaceutical industry to look beyond biologics for immunotherapy. A small molecule from AbbVie and Calico Life Sciences currently in early-stage clinical trials for solid tumors appears to improve the response to PD-1 inhibitors in mice with solid tumors. It also incurs a survival benefit when used on its own. In the results of a study published Oct. 4 in Nature, researchers from AbbVie, Calico and the Broad Institute at Harvard and MIT reported that mice with pancreatic, breast and metastatic cancer who were treated with an orally-administered small molecule, ABBV-CLS-484, alongside a PD-1 inhibitor outlived controls and had slower tumor growth. Mice that received the drug by itself had a smaller but still statistically significant survival benefit. Importantly, ABBV-CLS-484 also appeared to reduce T cell exhaustion in mice and reinvigorate exhausted human T cells, a sign that the drug may be able to stave off a major pathway of resistance for immunotherapies. “Resistance to PD-1 blockade is a major problem in oncology, as the majority of patients show primary resistance to [immune checkpoint blockade],” study co-lead Robert Manguso, Ph.D., of the Broad Institute, told Fierce Biotech Research in an email. “Even among responders, the majority of patients will develop adaptive or secondary resistance. We need new immunotherapies and combinations to improve overall response rates and treat resistant tumors.” ABBV-CLS-484 inhibits the activity of PTPN1 and PTPN2, both types of enzymes known as protein tyrosine phosphatases. Typically, they act as immune checkpoints by interfering with molecules along JAK/STAT signaling pathways, crucial elements of inflammation. This is helpful for keeping the immune system under control when it’s warding off pathogens, but not so much when it needs all hands on deck to destroy malignant cells, as Manguso explained. Inhibiting PTPN1 and PTPN2 unleashes that portion of the immune response, giving the body another weapon in its anticancer arsenal. Until recently, though, fighting cancer this way was wishful thinking. Protein tyrosine phosphatases like PTPN1 and PTPN2 were dismissed as “undruggable” targets for a number of reasons, one of which was an electrical problem, so to speak: Since the binding site was positively charged, it would only bind to negatively charged molecules—which usually can’t cross the outer membrane to get into the cell. Previous attempts to develop phosphatase inhibitors that could overcome this had failed. Still, the case for targeting PTPN1 and PTPN2 was growing. The results of CRISPR screening, published by Manguso’s lab in 2017, suggested that PTPN2 could improve responses to immunotherapy. Around the same time, work from other labs that suggested targeting PTPN1 and PTPN2 together could have a one-two punch of making T cells more effective against cancer while also sensitizing tumor cells to immunotherapy. “We knew that drugging a phosphatase would be challenging,” Manguso recalled. His lab partnered with AbbVie and Calico to find a solution, which ultimately came in the form of ABBV-CLS-484.“The medicinal chemistry lab at AbbVie did groundbreaking work on this project, and their belief in the promise of the target and the culture of optimism around it were big drivers of the eventual success,” Manguso said. Besides demonstrating that it’s possible to target a phosphatase—and that doing so can potentially both make immunotherapy more effective and overcome a major source of resistance—the drug may also provoke the pharmaceutical industry to look beyond biologics for immunotherapy, Manguso noted. Small molecules have more flexible dosing options, lower production costs and are easier to distribute and store, he said. “The development of small molecule immunotherapies could help this type of treatment reach even more patients in need of better treatment options,” Manguso said. ABBV-CLS-484 is a product of AbbVie’s ongoing partnership with Calico to find therapies for age-related diseases. The companies first signed a deal in 2014 where each party could co-invest up to $1.5 billion, with an original investment of $250,000 each and the possibility of an additional $500,000 each. They extended it twice since, adding another $1 billion each time. Editor's note: This article has been updated to clarify the details of the deal between AbbVie and Calico.

ImmunotherapyClinical Result

05 Oct 2023

·www.prnewswire.com

Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings, based on research conducted by AbbVie in collaboration with the Broad Institute and Calico, support the development of ABBV-CLS-484 as a promising new strategy for cancer immunotherapy. Titled "The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity," the paper highlights the novel structural insights and design that led to the discovery of ABBV-CLS-484 and its dual mechanism of action that targets tumor cells and suppresses their growth, as well as promotes the activation of several immune cell types to increase their anti-tumor activity.1 Researchers at the Broad previously identified protein tyrosine phosphatase non-receptor type 2 (PTPN2) and its closely related paralog PTPN1 as potential targets for cancer immunotherapy through an in vivo CRISPR screen.2 However, this challenging target class had previously been deemed "undruggable". AbbVie researchers overcame the challenges and discovered the dual PTPN2/N1 inhibitor, ABBV-CLS-484, through structure-based drug design and optimization of drug-like properties. Discovery scientists at AbbVie, the Broad, and Calico further uncovered the biology and mechanism of action of ABBV-CLS-484. Preclinical findings presented demonstrate that ABBV-CLS-484 treatment amplifies the tumor intrinsic response to interferon and increases the activation and function of several immune cell subsets promoting cellular pathways including JAK-STAT signaling in animal models. In murine cancer models resistant to PD-1 blockade, monotherapy ABBV-CLS-484 treatment generates robust anti-tumor immunity. Through in vivo studies and single cell transcriptional profiling of tumor-infiltrating lymphocytes from ABBV-CLS-484 treated mice, the team revealed that ABBV-CLS-484 inflames the tumor microenvironment and promotes NK and CD8+ T-cell function. In T cells, mechanistically, ABBV-CLS-484 induces epigenetic and metabolic changes resulting in a unique functional state causing increased cytotoxicity and reduced T-cell exhaustion and dysfunction. "Immunotherapies like PD-1 blockade have revolutionized cancer treatment; however, many patients do not respond well to them, and a significant unmet need remains," said Christina Baumgartner, Ph.D., co-first author and senior principal research scientist, AbbVie. "Through the extraordinary efforts of AbbVie's medicinal chemistry team to drug the undruggable, we now have a potential first-in-class PTPN2/N1 inhibitor. We're excited to share its biology and mechanism of action, and look forward to further evaluating it in the clinic." "This study is a powerful demonstration of how collaboration can bring together diverse expertise to advance our understanding of disease biology and lead to discoveries that support new treatment strategies for people living with cancer," said Marcia Paddock, M.D., Ph.D., co-author and director of oncology new target development at Calico. "We are proud to be working with both AbbVie and the Broad Institute and look forward to sharing additional progress from our clinical studies of this novel immunotherapy." ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors (NCT04777994). "This is an unprecedented opportunity to evaluate how immune responses work," said Robert Manguso, Ph.D., co-senior author on the study, associate member at the Broad, and assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School. "The ability to further explore this signaling pathway in clinical studies is really important." About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

ImmunotherapyPhase 1Pre-Clinical Data

100 Deals associated with Osunprotafib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	KR	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	ES	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	IL	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	FR	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	US	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	JP	AbbVie, Inc.	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	KR	Calico LLC	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	US	Calico LLC	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	FR	Calico LLC	09 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	IL	Calico LLC	09 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Osunprotafib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation